TiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol.
The IPO includes a 6.9 million share, 30-day over-allotment option for its underwriters. BofA Merrill Lynch and Cowen & Company acted as lead managers on the deal, according to TiGenix. The company anticipates that the offer will close on December 20, 2016.